Drugs & Targets Myriad submits sPMA for myChoice CDx with Lynparza in first-line maintenance therapy in advanced ovarian cancer February 14, 2020Vol.46 No.07
Drugs & Targets EMA accepts tucatinib application in HER2-positive breast cancer February 07, 2020Vol.46 No.06
Drugs & Targets EMA accepts application for belantamab mafodotin for multiple myeloma February 07, 2020Vol.46 No.06
Drugs & Targets European advisory group backs Pfizer’s Rituxan biosimilar February 07, 2020Vol.46 No.06
Drugs & Targets FDA, FTC collaborate to deter anti-competitive practices involving biosimilars February 07, 2020Vol.46 No.06
Drugs & Targets Predictive Technology Group and Atrin Pharmaceuticals collaborate on molecular diagnostic oncology development January 31, 2020Vol.46 No.5
Drugs & Targets FDA grants Tazverik accelerated approval as first treatment option for epithelioid sarcoma January 24, 2020Vol.46 No.04
Drugs & Targets FDA grants priority review of belantamab mafodotin for relapsed or refractory multiple myeloma January 24, 2020Vol.46 No.04
Drugs & Targets Myriad submits sPMA for BRACAnalysis CDx as companion diagnostic for Lynparza in metastatic castration-resistant prostate cancer January 24, 2020Vol.46 No.04
